Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.58 USD
-0.05 (-3.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Regulus Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 24 | 39 | 60 | 31 | 34 |
Receivables | 0 | 0 | 0 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 5 | 5 | 5 | 5 |
Total Current Assets | 28 | 44 | 65 | 37 | 40 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 31 | 47 | 68 | 38 | 42 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 1 | 1 |
Current Portion Long-Term Debt | 1 | 5 | 0 | 5 | 15 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 4 | 4 | 3 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 3 | 1 | 3 | 3 |
Total Current Liabilities | 9 | 12 | 5 | 12 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 5 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10 | 13 | 14 | 12 | 22 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 534 | 516 | 510 | 453 | 431 |
Retained Earnings | -513 | -483 | -455 | -427 | -411 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 21 | 33 | 55 | 26 | 20 |
Total Liabilities & Shareholder's Equity | 31 | 47 | 68 | 38 | 42 |
Total Common Equity | 21 | 33 | 55 | 26 | 20 |
Shares Outstanding | 20.20 | 14.60 | 14.60 | 6.70 | 2.10 |
Book Value Per Share | 1.05 | 2.28 | 3.76 | 3.89 | 9.53 |
Fiscal Year End for Regulus Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 95 | 98 | 24 | 31 | 37 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 4 | 4 | 4 | 4 |
Total Current Assets | 100 | 101 | 28 | 35 | 41 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 0 |
Investments & Advances | 1 | 10 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 104 | 114 | 31 | 38 | 44 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 0 | 0 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 1 | 1 | 2 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 2 | 5 | 4 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 2 | 2 | 2 |
Total Current Liabilities | 5 | 6 | 9 | 8 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 7 | 10 | 9 | 10 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 631 | 629 | 534 | 533 | 531 |
Retained Earnings | -533 | -522 | -513 | -505 | -497 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 98 | 108 | 21 | 28 | 34 |
Total Liabilities & Shareholder's Equity | 104 | 114 | 31 | 38 | 44 |
Total Common Equity | 98 | 108 | 21 | 28 | 34 |
Shares Outstanding | 65.40 | 65.40 | 20.20 | 19.40 | 19.40 |
Book Value Per Share | 1.50 | 1.64 | 1.05 | 1.46 | 1.75 |